Editas Stock Analysis

EDIT -  USA Stock  

USD 18.15  0.64  3.41%

The big decline in price over the last few months for Editas Medicine could raise concerns from private investors as the firm it trading at a share price of 18.15 on 2,842,900 in volume. The company management teams failed to add value to investors and positioning the firm supply of money to exploit market volatility in December. However, diversifying your holdings with Editas Medicine or any similar stocks can still protect your portfolios during high-volatility market scenarios. The stock standard deviation of daily returns for 90 days investing horizon is currently 4.13. This high volatility is attributed to the latest market swings and not so good earnings reports for some of the Editas Medicine partners.
Continue to Investing Opportunities.

Editas Stock Analysis 

 
Refresh
The Editas Medicine stock analysis report makes it easy to digest most publicly released information about Editas Medicine and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Editas Stock analysis module also helps to analyze the Editas Medicine price relationship with some important fundamental indicators such as market cap and management efficiency.

Editas Stock Analysis Notes

About 74.0% of the company shares are held by institutions such as insurance companies. The book value of Editas Medicine was currently reported as 8.68. The company recorded a loss per share of 3.23. Editas Medicine had not issued any dividends in recent years. Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. Editas Medicine, Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts. Editas Medicine operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 235 people. To learn more about Editas Medicine call Katrine Bosley at 617 401-9000 or check out https://www.editasmedicine.com.

Editas Medicine Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Editas Medicine's investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Editas Medicine or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Editas Medicine generated a negative expected return over the last 90 days
Editas Medicine has high historical volatility and very poor performance
The company reported the previous year's revenue of 24.49 M. Net Loss for the year was (213.56 M) with loss before overhead, payroll, taxes, and interest of (67.26 M).
Editas Medicine currently holds about 557.84 M in cash with (169.32 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 8.25.
Editas Medicine has a frail financial position based on the latest SEC disclosures
Roughly 74.0% of the company shares are held by institutions such as insurance companies
Latest headline from www.nasdaq.com: Sale by Robertson Michelle of 1744 shares of Editas Medicine

Editas Medicine Upcoming and Recent Events

Earnings reports are used by Editas Medicine to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Editas Medicine previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
Upcoming Quarterly Report24th of February 2022
Next Earnings Report4th of May 2022
Next Fiscal Quarter End31st of December 2021
Next Fiscal Year End24th of February 2022
Last Quarter Report30th of September 2021
Last Earning Announcement31st of December 2020

Editas Largest EPS Surprises

Earnings surprises can significantly impact Editas Medicine's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2019-08-06
2019-06-30-0.6228-0.69-0.067210 
2017-08-09
2017-06-30-0.5733-0.65-0.076713 
2017-05-15
2017-03-31-0.7654-0.85-0.084611 
View All Earnings Estimates

Editas Medicine SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Editas Medicine prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Editas Medicine investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Editas Medicine specific information freely available to individual and institutional investors to make a timely investment decision.
8th of November 2021
Financial Statements and Exhibits. Results of Operations and Financial Condition
View
28th of October 2021
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
View
29th of September 2021
Financial Statements and Exhibits. Other Events. Regulation FD Disclosure
View
8th of September 2021
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
View
4th of August 2021
Financial Statements and Exhibits. Results of Operations and Financial Condition
View
8th of June 2021
Submission of Matters to a Vote of Security Holders
View
14th of May 2021
Financial Statements and Exhibits. Entry into a Material Definitive Agreement
View
5th of May 2021
Financial Statements and Exhibits. Results of Operations and Financial Condition
View

Editas Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Editas Medicine is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Editas Medicine backward and forwards among themselves. Editas Medicine's institutional investor refers to the entity that pools money to purchase Editas Medicine's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Security TypeSharesValue
Exchange Traded Concepts LlcCommon Shares51.6 K1.4 M
Green Alpha Advisors LlcCommon Shares36.2 K961 K
Mcguire Investment Group LlcCommon Shares17.8 K472 K
Patriot Financial Group Insurance Agency LlcCommon Shares8.1 K215 K
Spire Wealth ManagementCommon Shares1.2 K31 K
Carroll Financial Associates IncCommon SharesK28 K
Koshinski Asset Management IncCommon Shares40010.6 K
Note, although Editas Medicine's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Editas Market Capitalization

The company currently falls under 'Mid-Cap' category with current market capitalization of 1.36 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Editas Medicine's market, we take the total number of its shares issued and multiply it by Editas Medicine's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Editas Profitablity

Editas Medicine's profitability indicators refer to fundamental financial ratios that showcase Editas Medicine's ability to generate income relative to its revenue or operating costs. If, let's say, Editas Medicine is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Editas Medicine's executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Editas Medicine's profitability requires more research than a typical breakdown of Editas Medicine's financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
Last ReportedProjected for 2022
Return on Investment(37.00) (39.92) 
Return on Average Assets(0.23) (0.25) 
Return on Average Equity(0.28) (0.29) 
Return on Invested Capital(0.42) (0.43) 
Return on Sales(1.50) (1.62) 

Management Efficiency

The entity has return on total asset (ROA) of (20.68) % which means that it has lost $20.68 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (41.55) %, meaning that it created substantial loss on money invested by shareholders. Editas Medicine management efficiency ratios could be used to measure how well editas medicine manages its routine affairs as well as how well it operates its assets and liabilities. Return on Investment is likely to drop to -39.92 in 2022. Return on Average Assets is likely to drop to -0.25 in 2022. Total Liabilities is likely to drop to about 183.5 M in 2022. Current Liabilities is likely to drop to about 54.8 M in 2022
Last ReportedProjected for 2022
Book Value per Share 7.72  8.33 
Enterprise Value over EBIT(31.50) (32.33) 
Enterprise Value over EBITDA(32.33) (33.18) 
Price to Book Value 12.77  10.42 
Tangible Assets Book Value per Share 8.79  11.50 
Enterprise Value4.7 B5.1 B
Tangible Asset Value658.5 M534 M

Technical Drivers

As of the 23rd of January, Editas Medicine shows the coefficient of variation of (373.81), and Mean Deviation of 3.09. Editas Medicine technical analysis allows you to utilize historical prices and volume patterns in order to determine a pattern that computes the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We were able to collect and analyze data for nineteen technical drivers for Editas Medicine, which can be compared to its rivals. Please confirm Editas Medicine information ratio, as well as the relationship between the potential upside and kurtosis to decide if Editas Medicine is priced favorably, providing market reflects its regular price of 18.15 per share. Given that Editas Medicine has jensen alpha of (1.03), we urge you to verify Editas Medicine's prevailing market performance to make sure the company can sustain itself at a future point.

Editas Medicine Price Movement Analysis

Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Exponential Moving Average is calculated by weighting recent values of Editas Medicine more heavily than older values. View also all equity analysis or get more info about exponential moving average overlap studies indicator.

Editas Medicine Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Editas Medicine insiders, such as employees or executives, is commonly permitted as long as it does not rely on Editas Medicine's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Editas Medicine insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
James Mullen over two weeks ago via Macroaxis 
Sale by James Mullen of 18252 shares of Editas Medicine
Eaton Bruce over a month ago via Macroaxis 
Acquisition by Eaton Bruce of 3472 shares of Editas Medicine subject to Rule 16b-3
Eaton Bruce over two months ago via Macroaxis 
Sale by Eaton Bruce of 287 shares of Editas Medicine
Connaughton Bernadette over two months ago via Macroaxis 
Acquisition by Connaughton Bernadette of 24732 shares of Editas Medicine subject to Rule 16b-3
James Mullen over three months ago via Macroaxis 
Sale by James Mullen of 13805 shares of Editas Medicine
James Mullen over three months ago via Macroaxis 
Acquisition by James Mullen of 36478 shares of Editas Medicine subject to Rule 16b-3
Reeve Emma over three months ago via Macroaxis 
Acquisition by Reeve Emma of 13736 shares of Editas Medicine subject to Rule 16b-3
Robertson Michelle over three months ago via Macroaxis 
Exercise or conversion by Robertson Michelle of 2500 shares of Editas Medicine subject to Rule 16b-3
Eaton Bruce over three months ago via Macroaxis 
Editas Medicine exotic insider transaction detected
Robertson Michelle over six months ago via Macroaxis 
Exercise or conversion by Robertson Michelle of 2500 shares of Editas Medicine subject to Rule 16b-3
Charles Albright over six months ago via Macroaxis 
Exercise or conversion by Charles Albright of 10000 shares of Editas Medicine subject to Rule 16b-3
Shearman Mark S over six months ago via Macroaxis 
Acquisition by Shearman Mark S of 52718 shares of Editas Medicine subject to Rule 16b-3

Editas Medicine Predictive Daily Indicators

Editas Medicine intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Editas Medicine stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Editas Medicine Forecast Models

Editas Medicine time-series forecasting models is one of many Editas Medicine's stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Editas Medicine's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

About Editas Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Editas Medicine stock is reacting to, or reflecting on a current stock market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Editas shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual stock such as Editas Medicine. By using and applying Editas Stock analysis, traders can create a robust methodology for identifying Editas entry and exit points for their positions.
Last ReportedProjected for 2022
EBITDA Margin(1.45) (1.57) 
Gross Margin 0.90  0.89 
Profit Margin(1.47) (1.58) 
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. Editas Medicine, Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts. Editas Medicine operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 235 people.

Current Editas Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Editas analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Editas analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
52.2Hold10Odds
Editas Medicine current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Editas analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Editas stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Editas Medicine, talking to its executives and customers, or listening to Editas conference calls.
Editas Analyst Advice Details

Editas Stock Analysis Indicators

Editas Medicine stock analysis indicators help investors evaluate how Editas Medicine stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Editas Medicine shares will generate the highest return on investment. By understating and applying Editas Medicine stock analysis, traders can identify Editas Medicine position entry and exit signals to maximize returns.
Quick Ratio10.96
Fifty Two Week Low19.63
Revenue Growth-90.10%
Shares Short Prior Month9.54M
Average Daily Volume Last 10 Day1.93M
Average Daily Volume In Three Month1.37M
Shares Percent Shares Out15.83%
Short Percent Of Float18.60%
Forward Price Earnings-5.98
Float Shares67.43M
Fifty Two Week High74.55
Enterprise Value To Ebitda-5.91
Fifty Day Average30.40
Two Hundred Day Average41.09
Enterprise Value To Revenue51.31
Continue to Investing Opportunities. Note that the Editas Medicine information on this page should be used as a complementary analysis to other Editas Medicine's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.

Complementary Tools for Editas Stock analysis

When running Editas Medicine price analysis, check to measure Editas Medicine's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Editas Medicine is operating at the current time. Most of Editas Medicine's value examination focuses on studying past and present price action to predict the probability of Editas Medicine's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Editas Medicine's price. Additionally, you may evaluate how the addition of Editas Medicine to your portfolios can decrease your overall portfolio volatility.
Watchlist Optimization
Optimize watchlists to build efficient portfolio or rebalance existing positions based on mean-variance optimization algorithm
Go
Transaction History
View history of all your transactions and understand their impact on performance
Go
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Go
Commodity Channel Index
Use Commodity Channel Index to analyze current equity momentum
Go
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Go
ETF Directory
Find actively traded Exchange Traded Funds (ETF) from around the world
Go
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Go
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Go
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Go
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Go
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Go
Is Editas Medicine's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Editas Medicine. If investors know Editas will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Editas Medicine listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Editas Medicine is measured differently than its book value, which is the value of Editas that is recorded on the company's balance sheet. Investors also form their own opinion of Editas Medicine's value that differs from its market value or its book value, called intrinsic value, which is Editas Medicine's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Editas Medicine's market value can be influenced by many factors that don't directly affect Editas Medicine's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Editas Medicine's value and its price as these two are different measures arrived at by different means. Investors typically determine Editas Medicine value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Editas Medicine's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.